«Ингибиторы ангиотензинпревращающего фермента или сартаны у больных с высоким риском развития осложнений сердечно-сосудистых заболеваний» – неправильный вопрос или нежелательный ответ
Аннотация
Об авторах
С. Р. ГиляревскийРоссия
В. А. Орлов
Россия
И. М. Кузьмина
Россия
М. В. Голшмид
Россия
Список литературы
1. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin - converting - enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000; 342: 145–53 [Errata, N Engl J Med 2000; 342: 784, 1376].
2. Fox K.M. European trial On reduction of cardiac events with Perindopril instable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double - blind, placebo - controlled, multicentretrial (the EUROPA study). Lancet 2003; 362: 782–8.
3. Nissen S.E., Tuzcu E.M., Libby P. et al. Effectof antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure.JAMA 2004; 292: 2217–26.
4. Braunwald E, Domanski M.J., Fowler S.E. et al. Angiotensin - converting - enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058–68.
5. Phillips L.S., Branch W.T., Cook C.B. et al. Clinicalinertia. Ann Intern Med 2001; 135: 825–34.
6. Giugliano D, Esposito K. Clinical inertiaas a clinical safeguard.JAMA 2011; 305: 1591–2.
7. Avignon A, Attali C, Sultan A et al. Clinical inertia: view points of general practitioners and diabetologists. Diabetes Metab 2012; 38 (Suppl. 3): S53–S58.
8. Cowart J.B., Taylor A.A. Should two - drug initial therapy for hypertension be recommended forallpatients? Curr Hypertens Rep 2012; 14: 324–32.
9. Pateland J.A., Fotis M.A. Comparison of Treatment of Patients With Congestive Heart Failure by Cardiologists Versus Noncardiologists. Am J Health Syst Pharm 2005; 62: 168–72.
10. Lichter A.S., McKinney R. Toward a harmonized and centralized conflict finterest disclosure: progress froman IOM initiative.JAMA 2012; 308: 2093–4.
11. Choudhry N.K., Fletcher R.H., Soumerai S.B. Systematicreview: the relationship between clinical experience and quality of healthcare. Ann Intern Med 2005; 142: 260–73.
12. Gerstein H.C., Bosch J, Dagenais G.R. et al. ORIGIN Trial Investigators. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia 2012; 367: 319–28.
13. Rizos E.C., Ntzani E.E., Bika E. et al. Associationbetween omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta - analysis.JAMA 2012; 308: 1024–33.
14. The ONTARGET Investigators. Telmisartan, Ramipril, or Bothin Patientsat High Risk for Vascular Events. N Engl J Med 2008; 358: 1547–59.
15. Piaggio G, Elbourne D.R., Pocock S.J. et al. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement.JAMA 2012; 308: 2594–604.
16. Savarese G, Costanzo P, Cleland J.G. et al. A meta - analysis reporting effects of angiotensin - converting enzyme inhibitors and angiotensin receptor blockers in patients with outheart failure. J Am Coll Cardiol 2013; 61: 131–42.
17. Moher D, Liberati A, Tetzlaff J, Altman D.G. PRISMA Group. Prefer redreporting items for systematic reviews and meta - analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006–12.
18. Van Vark L.C., Bertrand M, Akkerhuis K.M. et al. Angiotensin - converting enzyme inhibitors reduce mortality in hypertension: a meta - analysis of randomized clinical trials of renin - angiotensin - aldosterone system inhibitors in volving 158,998 patients. Eur Heart J 2012; 33: 2088–97.
Рецензия
Для цитирования:
Гиляревский С.Р., Орлов В.А., Кузьмина И.М., Голшмид М.В. «Ингибиторы ангиотензинпревращающего фермента или сартаны у больных с высоким риском развития осложнений сердечно-сосудистых заболеваний» – неправильный вопрос или нежелательный ответ. Системные гипертензии. 2013;(1):35-38.
For citation:
Gilyarevsky S.R., Orlov V.A., Kuzmina I.M., Golshmid M.V. Angiotensin-converting enzyme inhibitors or sartans in patients at high risk for cardiovascular events: a wrong question or an undesirable answer. Systemic Hypertension. 2013;(1):35-38.
Послать статью по эл. почте 